Maven Securities’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.49M | Buy |
42,117
+23,011
| +120% | +$1.91M | 0.08% | 21 |
|
|
2025
Q1 | $1.55M | Buy |
19,106
+8,214
| +75% | +$666K | 0.05% | 75 |
|
|
2024
Q4 | $981K | Buy |
10,892
+828
| +8% | +$74.6K | 0.02% | 116 |
|
|
2024
Q3 | $994K | Sell |
10,064
-77,095
| -88% | -$7.62M | 0.02% | 142 |
|
|
2024
Q2 | $8.08M | Buy |
87,159
+37,638
| +76% | +$3.49M | 0.18% | 13 |
|
|
2024
Q1 | $4.7M | Buy |
49,521
+18,121
| +58% | +$1.72M | 0.28% | 45 |
|
|
2023
Q4 | $2.8M | Buy |
31,400
+275
| +0.9% | +$24.6K | 0.06% | 64 |
|
|
2023
Q3 | $2.27M | Sell |
31,125
-8,410
| -21% | -$614K | 0.03% | 70 |
|
|
2023
Q2 | $3.29M | Buy |
+39,535
| New | +$3.29M | 0.05% | 50 |
|
|
2022
Q4 | – | Sell |
-10,539
| Closed | -$836K | – | 526 |
|
|
2022
Q3 | $836K | Buy |
+10,539
| New | +$836K | 0.02% | 213 |
|
|
2022
Q2 | – | Sell |
-4,292
| Closed | -$386K | – | 604 |
|
|
2022
Q1 | $386K | Buy |
+4,292
| New | +$386K | 0.01% | 231 |
|
|
2021
Q3 | – | Sell |
-6,200
| Closed | -$851K | – | 846 |
|
|
2021
Q2 | $851K | Sell |
6,200
-11,678
| -65% | -$1.6M | 0.03% | 245 |
|
|
2021
Q1 | $2.4M | Buy |
17,878
+12,981
| +265% | +$1.74M | 0.11% | 120 |
|
|
2020
Q4 | $706K | Sell |
4,897
-15,676
| -76% | -$2.26M | 0.07% | 282 |
|
|
2020
Q3 | $2.32M | Buy |
+20,573
| New | +$2.32M | 0.19% | 67 |
|
|
2018
Q4 | – | Sell |
-7,300
| Closed | -$703K | – | 175 |
|
|
2018
Q3 | $703K | Buy |
+7,300
| New | +$703K | 0.26% | 85 |
|
|
2017
Q4 | – | Sell |
-2,500
| Closed | -$215K | – | 59 |
|
|
2017
Q3 | $215K | Buy |
+2,500
| New | +$215K | 0.11% | 34 |
|
|
2017
Q1 | – | Sell |
-2,353
| Closed | -$140K | – | 65 |
|
|
2016
Q4 | $140K | Buy |
+2,353
| New | +$140K | 0.13% | 29 |
|